Research programme: respiratory syncytial virus infection therapeutics - Enanta PharmaceuticalsAlternative Names: EDP 938; EP 023938; Non-fusion inhibitors - Enanta; RSV therapeutics - Enanta
Latest Information Update: 12 Jan 2017
At a glance
- Originator Enanta Pharmaceuticals
- Class Antivirals
- Mechanism of Action Viral fusion protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Respiratory syncytial virus infections